The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,418
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,009
CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential
Blenke, E. O., Evers, M. J. W., Mastrobattista, E., & John van der, O. O. S. T. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.002 · Cited by 63
Efficient In Vivo Liver-Directed Gene Editing Using CRISPR/Cas9
Singh, K., Evens, H., Nair, N., Rincón, M. Y., Sarcar, S., Samara-Kuko, E., Chuah, M., & VandenDriessche, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.023 · Cited by 63
Xie, H., Tang, L., He, X., Liu, X., Zhou, C., Liu, J., Ge, X., Li, J., Liu, C., Zhao, J., et al. (2017) · Biotechnology Journal · doi:10.1002/biot.201700561 · Cited by 62
Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9
Choi, G. C. G., Zhou, P., Yuen, C. T. L., Chan, B. K. C., Xu, F., Bao, S., Chu, H. Y., Thean, D., Tan, K., Wong, K. H., et al. (2019) · Nature Methods · doi:10.1038/s41592-019-0473-0 · Cited by 63
Efficient generation of Knock-in/Knock-out marmoset embryo via CRISPR/Cas9 gene editing
Kumita, W., Sato, K., Suzuki, Y., Kurotaki, Y., Harada, T., Zhou, Y., Kishi, N., Sato, K., Aiba, A., Sakakibara, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49110-3 · Cited by 64
Customizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer’s Disease—A Narrative Review
Barman, N. C., Khan, M. N. M., Islam, M., Nain, Z., Roy, R. K., Haque, A., & BARMAN, S. K. (2020) · Neurology and Therapy · doi:10.1007/s40120-020-00218-z · Cited by 65
CRISPR/Cas Technology in Pig-to-Human Xenotransplantation Research
Ryczek, N., Hryhorowicz, M., Zeyland, J., Lipiński, D., & Słomski, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063196 · Cited by 66
Genome editing reagent delivery in plants
Ghogare, R., Ludwig, Y., Bueno, G. M., Slamet-Loedin, I. H., & Dhingra, A. (2021) · Transgenic Research · doi:10.1007/s11248-021-00239-w · Cited by 61
Ouellet, D. L., Cherif, K., Rousseau, J., & Tremblay, J. P. (2016) · Gene Therapy · doi:10.1038/gt.2016.89 · Cited by 64
A Split Staphylococcus aureus Cas9 as a Compact Genome-Editing Tool in Plants
Kaya, H., Ishibashi, K., & Toki, S. (2017) · Plant and Cell Physiology · doi:10.1093/pcp/pcx034 · Cited by 61
Scrudato, M. L., Poulard, K., Sourd, C., Tomé, S., Klein, A. F., Corre, G., Huguet-Lachon, A., Furling, D., Gourdon, G., & Buj‐Bello, A. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.021 · Cited by 67
Enhancing gene editing specificity by attenuating DNA cleavage kinetics
Miller, J. C., Patil, D. P., Xia, D. F., Paine, C. B., Fauser, F., Richards, H. W., Shivak, D. A., Bendaña, Y. R., Hinkley, S. J., Scarlott, N. A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0186-z · Cited by 63
Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9
Li, H., Sheng, C., Liu, H., Wang, S., Zhao, J., Yang, L., Jia, L., Li, P., Wang, L., Xie, J., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02080 · Cited by 60
CRISPR-Cas gene editing technology and its application prospect in medicinal plants
Guo, M., Chen, H., Dong, S., Zhang, Z., & Luo, H. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00584-w · Cited by 66
Wang, Y., Wang, Y., Pan, D., Yu, H., Zhang, Y., Chen, W., Li, F., Wu, Z., & Ji, Q. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111418 · Cited by 63
Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges
Ueda, J., Yamazaki, T., & Funakoshi, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054778 · Cited by 60
Essential RNA-Based Technologies and Their Applications in Plant Functional Genomics
Teotia, S., Singh, D., Tang, X., & Tang, G. (2016) · Trends in biotechnology · doi:10.1016/j.tibtech.2015.12.001 · Cited by 60
CRISPR/Cas9 and cancer targets: future possibilities and present challenges
White, M. K., & Khalili, K. (2016) · Oncotarget · doi:10.18632/oncotarget.7104 · Cited by 62
Wang, J., Zhang, C., & Feng, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15039 · Cited by 61
CRISPR system: Discovery, development and off-target detection
Chen, S., Yao, Y., Zhang, Y., & Fan, G. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109577 · Cited by 60
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Genome-wide detection of CRISPR editing in vivo using GUIDE-tag
Liang, S.-Q., Liu, P., Smith, J. L., Mintzer, E., Maitland, S., Dong, X., Yang, Q., Lee, J., Haynes, C. M., Zhu, L. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28135-9 · Cited by 54
Caneva, A. D., Porro, F., Bortolussi, G., Sola, R., Lisjak, M., Barzel, A., Giacca, M., Kay, M. A., Vlahoviček, K., Zentilin, L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128863 · Cited by 61
Wang, L., Breton, C. A., Warzecha, C. C., Bell, P. L., Yan, H., He, Z., White, J., Zhu, Y., Li, M., Buza, E. L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.020 · Cited by 61
CRISPR/Cas9 system: a reliable and facile genome editing tool in modern biology
Javaid, D., Ganie, S. Y., Hajam, Y. A., & Reshi, M. S. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07880-6 · Cited by 65
Current trends of clinical trials involving CRISPR/Cas systems
Zhang, S., Wang, Y., Mao, D., Wang, Y., Zhang, H., Pan, Y., Wang, Y., Teng, S., & Huang, P. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1292452 · Cited by 62
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 63
Self-citationCRISPR-Cas9 for medical genetic screens: applications and future perspectives
Xue, H.-Y., Ji, L.-J., Gao, A.-M., Liu, P., He, J.-D., & Lu, X. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103409 · Cited by 62
High-fidelity SaCas9 identified by directional screening in human cells
Xie, H., Ge, X., Yang, F., Wang, B., Li, S., Duan, J., Lv, X., Cheng, C., Song, Z., Liu, C., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000747 · Cited by 59
Tóth, E., Weinhardt, N., Bencsura, P., Huszár, K., Kulcsár, P. I., Tálas, A., Fodor, E., & Welker, E. (2016) · Biology Direct · doi:10.1186/s13062-016-0147-0 · Cited by 58
Ma, L., Ruan, J., Song, J. W., Wen, L., Yang, D., Zhao, J., Xia, X., Chen, Y. E., Zhang, J., & Xu, J. (2020) · Nature Communications · doi:10.1038/s41467-020-19842-2 · Cited by 60
Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review
Lee, M. H., Shin, J. I., Yang, J. W., Lee, K. H., Cha, D. H., Hong, J. B., Park, Y., Choi, E., Tizaoui, K., Koyanagi, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031337 · Cited by 68
A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment
Yang, X., & Zhang, B. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01117-w · Cited by 58
Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression
Seem, K., Kaur, S., Kumar, S., & Mohapatra, T. (2024) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2024.2320659 · Cited by 59
Kim, H. S., Kweon, J., & Kim, Y. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01212-3 · Cited by 68
New frontiers in CRISPR: Addressing antimicrobial resistance with Cas9, Cas12, Cas13, and Cas14
Agha, A. S. A. A., Al-Samydai, A. M., & Aburjai, T. A. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42013 · Cited by 63
Recent advances in therapeutic gene-editing technologies
Liu, D., Cao, D., & Han, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.026 · Cited by 70
Hu, J. H., Davis, K. M., & Liu, D. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.009 · Cited by 61
A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research
Miano, J. M., Zhu, Q. M., & Lowenstein, C. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.304790 · Cited by 58
CRISPR/Cas9, a powerful tool to target human herpesviruses
van Diemen, F. R., & Lebbink, R. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12694 · Cited by 59
Motta, B. M., Pramstaller, P. P., Hicks, A. A., & Rossini, A. (2017) · Stem Cells International · doi:10.1155/2017/8960236 · Cited by 64
Rational Design of Mini-Cas9 for Transcriptional Activation
Ma, D., Peng, S., Huang, W., Cai, Z., & Xie, Z. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00404 · Cited by 59
Diakatou, M., Manès, G., Bocquet, B., Meunier, I., & Kalatzis, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102542 · Cited by 59
Progress and challenges towards CRISPR/Cas clinical translation
Rosenblum, D., Gutkin, A., Dammes, N., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.004 · Cited by 61
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System
Lattanzi, A., Duguez, S., Moiani, A., Izmiryan, A., Barbon, E., Martin, S., Mamchaoui, K., Mouly, V., Bernardi, F., Mavilio, F., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.02.004 · Cited by 65
Lee, J., Lee, J. Y., Song, D. W., Bae, H. S., Doo, H. M., Yu, H. S., Lee, K. J., Kim, H. K., Hwang, H., Kwak, G., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1070 · Cited by 57
Schmidt, M. J., Gupta, A. K., Bednarski, C., Gehrig-Giannini, S., Richter, F. M., Pitzler, C., Gamalinda, M., Galonska, C., Takeuchi, R., Wang, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24454-5 · Cited by 58
Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9
Ashok, B., Peppas, N. A., & Wechsler, M. E. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102728 · Cited by 62
CRISPR-Cas9 Gene Editing for Fruit and Vegetable Crops: Strategies and Prospects
Wan, L., Wang, Z., Tang, M., Hong, D., Sun, Y., Ren, J. M., Zhang, N., & Zeng, H. (2021) · Horticulturae · doi:10.3390/horticulturae7070193 · Cited by 64
Chien, Y., Hsiao, Y., Chou, S., Lin, T.-Y., Yarmishyn, A. A., Lai, W., Lee, M., Lin, Y., Lin, T.-W., Hwang, D., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 59
Whitworth, K. M., Benne, J. A., Spate, L. D., Murphy, S. L., Samuel, M., Murphy, C. N., Richt, J. A., Walters, E. M., Prather, R. S., & Wells, K. D. (2016) · Transgenic Research · doi:10.1007/s11248-016-9989-6 · Cited by 57
Feasibility of a Conditional Knockout System for Chlamydia Based on CRISPR Interference
Ouellette, S. P. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00059 · Cited by 55
Klompe, S. E., & Sternberg, S. H. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0012 · Cited by 57
Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases
Kolli, N., Lü, M., Maiti, P., Rossignol, J., & Dunbar, G. L. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.07.007 · Cited by 59
Martella, A., Firth, M. A., Taylor, B., Göppert, A., Cuomo, E. M., Roth, R. G., Dickson, A. J., & Fisher, D. I. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00527 · Cited by 56
Zhang, G., Zeng, T., Dai, Z., & Dai, X. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.03.001 · Cited by 64
CRISPR technologies for the treatment of Duchenne muscular dystrophy
Choi, E., & Koo, T. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.002 · Cited by 57
Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies
Hasanzadeh, A., Alamdaran, M., Ahmadi, S., Nourizadeh, H., Bagherzadeh, M. A., Jahromi, M. A. M., Simon, P. D., Karimi, M., & Hamblin, M. R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.036 · Cited by 59
Wang, J., Chen, R., Zhang, R., Ding, S., Zhang, T., Yuan, Q., Guan, G., Chen, X., Zhang, T., Zhuang, H., et al. (2017) · Theranostics · doi:10.7150/thno.18114 · Cited by 56
The Conspicuity of CRISPR-Cpf1 System as a Significant Breakthrough in Genome Editing
Bayat, H., Modarressi, M. H., & Rahimpour, A. (2017) · Current Microbiology · doi:10.1007/s00284-017-1406-8 · Cited by 56
Fei, J., Lou, W. P.-K., Knapp, D., Murawala, P., Gerber, T., Taniguchi, Y., Nowoshilow, S., Khattak, S., & Tanaka, E. M. (2018) · Nature Protocols · doi:10.1038/s41596-018-0071-0 · Cited by 57
Zhu, Y., Biernacka, A., Pardo, B., Dojer, N., Forey, R., Skrzypczak, M., Fongang, B., Nde, J., Yousefi, R., Pasero, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10332-8 · Cited by 60
Cytosine base editing systems with minimized off-target effect and molecular size
Li, A., Mitsunobu, H., Yoshioka, S., Suzuki, T., Kondo, A., & Nishida, K. (2022) · Nature Communications · doi:10.1038/s41467-022-32157-8 · Cited by 57
Methods and applications of CRISPR/Cas system for genome editing in stem cells
Yang, G., & Huang, X. (2019) · Cell Regeneration · doi:10.1016/j.cr.2019.08.001 · Cited by 55
Targeting Cancer with CRISPR/Cas9-Based Therapy
Balon, K., Sheriff, A., Jackow, J., & Łaczmański, Ł. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010573 · Cited by 60
Systematic decomposition of sequence determinants governing CRISPR/Cas9 specificity
Fu, R., He, W., Dou, J., Villarreal, O. D., Bedford, E., Wang, H. H., Hou, C., Zhang, L., Wang, Y., Ma, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28028-x · Cited by 59
Masarwy, R., Stotsky‐Oterin, L., Elisha, A., Hazan‐Halevy, I., & Peer, D. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115359 · Cited by 59
An ‘Omics’ Perspective on Cardiomyopathies and Heart Failure
Raghow, R. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.007 · Cited by 58
Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles
Yu, K., Natanson, H., & Dunbar, C. E. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.107 · Cited by 59
Yang, H., & Chen, P. (2017) · Virus Research · doi:10.1016/j.virusres.2017.06.010 · Cited by 54
Advances in gene therapy for hemophilia: basis, current status, and future perspectives
Ohmori, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2513-4 · Cited by 60
Computational Tools and Resources Supporting CRISPR-Cas Experiments
Śledziński, P., Nowaczyk, M., & Olejniczak, M. (2020) · Cells · doi:10.3390/cells9051288 · Cited by 57
Detection and Modulation of DNA Translocations During Multi-Gene Genome Editing in T Cells
Bothmer, A., Gareau, K. W., Abdulkerim, H. S., Buquicchio, F. A., Cohen, L. A., Viswanathan, R., Zuris, J. A., Marco, E., Fernández, C. A., Myer, V. E., et al. (2020) · The CRISPR Journal · doi:10.1089/crispr.2019.0074 · Cited by 56
Precise base editing with CC context-specificity using engineered human APOBEC3G-nCas9 fusions
Liu, Z., Chen, S., Shan, H., Jia, Y., Chen, M., Song, Y., Lai, L., & Li, Z. (2020) · BMC Biology · doi:10.1186/s12915-020-00849-6 · Cited by 53
Efficient viral delivery of Cas9 into human safe harbor
Hayashi, H., Kubo, Y., Izumida, M., & Matsuyama, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78450-8 · Cited by 54
CRISPR-Cas systems: ushering in the new genome editing era
Rojo, F. P., Nyman, R. K. M., Johnson, A. A. T., Pazos-Navarro, M., Ryan, M. H., Erskine, W., & Kaur, P. (2018) · Bioengineered · doi:10.1080/21655979.2018.1470720 · Cited by 58
Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing
Rabinowitz, R., & Offen, D. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.009 · Cited by 58
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Huang, K. L., Zapata, D. A., Tang, Y., Teng, Y., & Li, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121876 · Cited by 61
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 59
Crop bioengineering via gene editing: reshaping the future of agriculture
Atia, M. A. M., Jiang, W., Sedeek, K., Butt, H., & Mahfouz, M. M. (2024) · Plant Cell Reports · doi:10.1007/s00299-024-03183-1 · Cited by 59
In vivo base editing extends lifespan of a humanized mouse model of prion disease
An, M., Davis, J. R., Levy, J. M., Serack, F. E., Harvey, J. W., Brauer, P. P., Pirtle, C. P., Berríos, K. N., Newby, G. A., Yeh, W.-H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03466-w · Cited by 58
Heritability of targeted gene modifications induced by plant-optimized CRISPR systems
Mao, Y., Botella, J. R., & Zhu, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2380-1 · Cited by 55
Genome editing for inborn errors of metabolism: advancing towards the clinic
Schneller, J. L., Lee, C. M., Bao, G., & Venditti, C. P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0798-4 · Cited by 57
The Hope and Hype of CRISPR-Cas9 Genome Editing
Musunuru, K. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.1713 · Cited by 59
CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy
Chen, S., Yu, X., & Guo, D. (2018) · Viruses · doi:10.3390/v10010040 · Cited by 54
Bouwman, B. A. M., & Crosetto, N. (2018) · Genes · doi:10.3390/genes9120632 · Cited by 65
Adenovirus vectors in hematopoietic stem cell genome editing
Li, C., & Lieber, A. (2019) · FEBS Letters · doi:10.1002/1873-3468.13668 · Cited by 53
Hsu, M., Yu, F.-J., Chang, Y., Huang, K.-L., Pham, N. N., Truong, V. A., Lin, M., Nguyen, N. T. K., Hwang, S., & Hu, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120094 · Cited by 54
Charlier, J., Nadon, R., & Makarenkov, V. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab112 · Cited by 59
Personalized gene and cell therapy for Duchenne Muscular Dystrophy
Barthélémy, F., & Wein, N. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.06.009 · Cited by 57
Catalytic-state structure and engineering of Streptococcus thermophilus Cas9
Zhang, Y., Zhang, H., Xu, X., Wang, Y., Chen, W., Wang, Y., Wu, Z., Tang, N., Wang, Y., Zhao, S., et al. (2020) · Nature Catalysis · doi:10.1038/s41929-020-00506-9 · Cited by 49
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 63
Efficient Homology-Directed Repair with Circular Single-Stranded DNA Donors
Iyer, S., Mir, A., Vega‐Badillo, J., Roscoe, B. P., Ibraheim, R., Zhu, L. J., Lee, J., Liu, P., Luk, K., Mintzer, E., et al. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0058 · Cited by 63
CRISPR/Cas9: a tool to eradicate HIV-1
Bhowmik, R., & Chaubey, B. (2022) · AIDS Research and Therapy · doi:10.1186/s12981-022-00483-y · Cited by 58
Abbasi, A. F., Asim, M. N., & Dengel, A. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06013-w · Cited by 60
Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field
He, Z., Men, K., Qin, Z., Yang, Y., Xu, T., & Wei, Y.-Q. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9033-0 · Cited by 55
Bollen, Y., Post, J. B., Koo, B., & Snippert, H. J. G. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky571 · Cited by 53
Peng, H., Zheng, Y., Zhao, Z., Liu, T., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty558 · Cited by 57
Xiao, Q., Chen, S., Wang, Q., Liu, Z., Liu, S., Deng, H., Hou, W., Wu, D., Xiong, Y., Li, J., et al. (2019) · Retrovirology · doi:10.1186/s12977-019-0477-y · Cited by 56
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
